BioWorld MedTech

Dec. 18, 2012

Boston Scientific to study next-gen pacing leads

The first patient has been implanted with the Boston Scientific next generation Ingevity pacing leads in a clinical trial designed to establish the safety, performance and effectiveness of the leads, the company reported. Read More

Washington roundup: Obama says no to device tax delay, argues 'new customers'

International report: ConvaTec reports launching of its operations in India

Financings roundup: Angel Medical closes on aggregate $27.5M round

Agreements/contracts: Baylor Health Care, Scott & White combining systems

Deals roundup: Florida Blue to acquire Diagnostic Clinic in Largo

Court report: Orthofix resolves investigation of its bone growth business

People in the News

Product Briefs

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...